Cellular senescence contributes to Alzheimer’s disease (AD) pathogenesis. Treatments that remove senescent cells, senolytics, improve brain outcomes in AD mice with amyloid-β or tau deposition. 3xTgAD mice develop both AD neuropathologies; however, Ng et al. report low p16INK4a-associated senescence in the brain. Senolytic treatment by genetic removal; dasatinib with quercetin (D+Q), which enter the brain; and ABT-263 with limited brain penetrance all reduced AD neuropathology. Refined measures of senescence and brain exposure would help clarify the benefits of senolytics despite low p16INK4a-associated senescence and potential limited brain penetrance.
BrelstaffJH, MasonM, KatsinelosT, McEwanWA, GhettiB, TolkovskyAM, SpillantiniMG (2021) Microglia become hypofunctional and release metalloproteases and tau seeds when phagocytosing live neurons with P301S tau aggregates eab. Sci Adv7, 49804980.
CoppeJP, PatilCK, RodierF, SunY, MunozDP, GoldsteinJ, NelsonPS, DesprezPY, CampisiJ (2008) Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol6, 2853–2868.
9.
WileyCD, FlynnJM, MorrisseyC, LebofskyR, ShugaJ, DongX, UngerMA, VijgJ, MelovS, CampisiJ (2017) Analysis of individual cells identifies cell-to-cell variability following induction of cellular senescence. Aging Cell16, 1043–1050.
10.
DehkordiSK, WalkerJ, SahE, BennettE, AtrianF, FrostB, WoostB, BennettRE, OrrTC, ZhouY (2021) Profiling senescent cells in human brains reveals neurons with CDKN2D/p19 and tau neuropathology. Nat Aging1, 1107–1116.
11.
MusiN, ValentineJM, SickoraKR, BaeuerleE, ThompsonCS, ShenQ, OrrME (2018) Tau protein aggregation is associated with cellular senescence in the brain. Aging Cell17, e12840.
12.
GaikwadS, PuangmalaiN, BittarA, MontalbanoM, GarciaS, McAllenS, BhattN, SonawaneM, SenguptaU, KayedR (2021) Tau oligomer induced HMGB1 release contributes to cellular senescence and neuropathology linked to Alzheimer’s disease and frontotemporal dementia. Cell Rep36, 109419.
13.
HussongSA, BanhAQ, Van SkikeCE, DorigattiAO, HernandezSF, HartMJ, FerranB, MakhloufH, GaczynskaM, OsmulskiPA, McAllenSA, DineleyKT, UngvariZ, PerezVI, KayedR, GalvanV (2023) Soluble pathogenic tau enters brain vascular endothelial cells and drives cellular senescence and brain microvascular dysfunction in a mouse model of tauopathy. Nat Commun14, 2367.
14.
BhatR, CroweEP, BittoA, MohM, KatsetosCD, GarciaFU, JohnsonFB, TrojanowskiJQ, SellC, TorresC (2012) Astrocyte senescence as a component of Alzheimer’s disease. PLoS One7, e45069.
BussianTJ, AzizA, MeyerCF, SwensonBL, van DeursenJM, BakerDJ (2018) Clearance of senescent glial cells prevents tau-dependent pathology and cognitive decline. Nature562, 578–582.
18.
BryantAG, HuM, CarlyleBC, ArnoldSE, FroschMP, DasS, HymanBT, BennettRE (2020) Cerebrovascular Senescence is associated with tau pathology in Alzheimer’s disease. Front Neurol11, 575953.
19.
WangW, WuJ, ZhangZ, TongT (2001) Characterization of regulatory elements on the promoter region of p16(INK4a) that contribute to overexpression of p16 in senescent fibroblasts. J Biol Chem276, 48655–48661.
20.
HudginsAD, TazearslanC, TareA, ZhuY, HuffmanD, SuhY (2018) Age- and tissue-specific expression of senescence biomarkers in mice. Front Genet9, 59.
RoyAL, SierraF, HowcroftK, SingerDS, SharplessN, HodesRJ, WilderEL, AndersonJM (2020) A blueprint for characterizing senescence. Cell183, 1143–1146.
23.
GongX, LiL, WeiH, LiuB, ZhouC, ZhangG, LiuK, LinD, GongB, WeiS, LiY, MiY, WangY, WangJ (2021) A higher dose of dasatinib may increase the possibility of crossing the blood–brain barrier in the treatment of patients with Philadelphia chromosome–positive acute lymphoblastic leukemia. , 1265-1271. Clin Ther43, 1265–1271.e1261.
24.
IshisakaA, IchikawaS, SakakibaraH, PiskulaMK, NakamuraT, KatoY, ItoM, MiyamotoK-i, TsujiA, KawaiY, TeraoJ (2011) Accumulation of orally administered quercetin in brain tissue and its antioxidative effects in rats. Free Radic Biol Med51, 1329–1336.
25.
PorkkaK, KoskenvesaP, LundánT, RimpiläinenJ, MustjokiS, SmyklaR, WildR, LuoR, ArnanM, BrethonB, EccersleyL, Hjorth-HansenH, HöglundM, KlamovaH, KnutsenH, ParikhS, RaffouxE, GruberF, Brito-BabapulleF, DombretH, DuarteRF, ElonenE, PaquetteR, ZwaanCM, LeeFYF (2008) Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome–positive leukemia. Blood112, 1005–1012.
26.
WiczkowskiW, SkiporJ, MisztalT, Szawara-NowakD, TopolskaJ, PiskulaMK (2015) Quercetin and isorhamnetin aglycones are the main metabolites of dietary quercetin in cerebrospinal fluid. Mol Nutr Food Res59, 1088–1094.
FarrJN, SaulD, DoolittleML, KaurJ, RowseyJL, VosSJ, FroemmingMN, LagnadoAB, ZhuY, WeivodaM, IkenoY, PignoloRJ, NiedernhoferLJ, RobbinsPD, JurkD, PassosJF, LeBrasseurNK, TchkoniaT, KirklandJL, MonroeDG, KhoslaS (2023) Local senolysis in aged mice only partially replicates the benefits of systemic senolysis. J Clin Invest133.
33.
JurkD, WangC, MiwaS, MaddickM, KorolchukV, TsolouA, GonosES, ThrasivoulouC, SaffreyMJ, CameronK, von Zglinicki ZglinickiT (2012) Postmitotic neurons develop a p21-dependent senescence-like phenotype driven by a DNA damage response. Aging Cell11, 996–1004.
34.
Nava CatorceM, AceroG, GevorkianG (2021) Age- and sex-dependent alterations in the peripheral immune system in the 3xTg-AD mouse model of Alzheimer’s disease: Increased proportion of CD3+CD4-CD8- double-negative T cells in the blood. J Neuroimmunol360, 577720.
35.
St-AmourI, PareI, TremblayC, CoulombeK, BazinR, CalonF (2014) IVIg protects the 3xTg-AD mouse model of Alzheimer’s disease from memory deficit and Abeta pathology. J Neuroinflammation11, 54.
36.
MarcheseM, CowanD, HeadE, MaD, KarimiK, AshthorpeV, KapadiaM, ZhaoH, DavisP, SakicB (2014) Autoimmune manifestations in the 3xTg-AD model of Alzheimer’s disease. J Alzheimers Dis39, 191–210.
37.
YabluchanskiyA, TarantiniS, BalasubramanianP, KissT, CsipoT, FulopGA, LipeczA, AhireC, DelFaveroJ, Nyul-TothA, SonntagWE, SchwartzmanML, CampisiJ, CsiszarA, UngvariZ (2020) Pharmacological or genetic depletion of senescent astrocytes prevents whole brain irradiation-induced impairment of neurovascular coupling responses protecting cognitive function in mice. Geroscience42, 409–428.
38.
RiesslandM, OrrME (2023) Translating the biology of aging into new therapeutics for Alzheimer’s disease: Senolytics. J Prev Alzheimers Dis10, 633–646.
39.
SierraF (2016) The emergence of geroscience as an interdisciplinary approach to the enhancement of health span and life span. , . Cold Spring Harb Perspect Med6, a025163.
40.
JusticeJN, NambiarAM, TchkoniaT, LeBrasseurNK, PascualR, HashmiSK, PrataL, MasternakMM, KritchevskySB, MusiN, KirklandJL (2019) Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study. EBioMedicine40, 554–563.
41.
HicksonLJ, Langhi PrataLGP, BobartSA, EvansTK, GiorgadzeN, HashmiSK, HerrmannSM, JensenMD, JiaQ, JordanKL, KelloggTA, KhoslaS, KoerberDM, LagnadoAB, LawsonDK, LeBrasseurNK, LermanLO, McDonaldKM, McKenzieTJ, PassosJF, PignoloRJ, PirtskhalavaT, SaadiqIM, SchaeferKK, TextorSC, VictorelliSG, VolkmanTL, XueA, WentworthMA, Wissler GerdesEO, ZhuY, TchkoniaT, KirklandJL (2019) Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease. {EBioMedicine47, 446–456.
